Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Study of PRAX-628 in Focal Onset or Primary Generalized Tonic-Clonic Seizures
2024-517061-16-01Phase 2Completed
- Sponsor
- Praxis Precision Medicines
- Start
- Feb 2025
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of vormatrigine in Focal onset seizure, generalized tonic-clonic seizure (GTCS) and epilepsy, sponsored by Praxis Precision Medicines. Primary endpoint: Median percent change in monthly (28 days) seizure frequency. Started Feb 2025; status: completed.
02
Drugs
vormatrigine
03
Conditions
Focal onset seizuregeneralized tonic-clonic seizure (GTCS)epilepsy
Beyond the preview
Go deeper on 2024-517061-16-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517061-16-01.